xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

397

Orlandi et al.

Lund 1063 2004 2 DBRCT (n = 167) 20 week course Combined symptom scores Individual symptom score HR-QoL (SF36) Peak nasal flow Symptom score individual symptom scores and peak nasal flow. No change in HRQoL. Giger 1065 2003 2 DBRCT (n = 112) Beclamethasone Budesonide improved combined symptom score, 1. Budesonide 128 μ gBID 2. Placebo

groups in any outcome measures.

patients with improved symptoms in both

treatment arms. No

difference between active treatment groups.

symptom scores in both groups as compared to placebo.

No reduction in recurrence rate of CRS following ESS.

Qvarnberg 504 1992 2 DBRCT (n = 40) Budesonide 200 μ gBID Placebo No significant differences in treatment outcomes between groups. Sykes 1074 1986 2 DBRCT (n = 50) 1. 20 μ g dexamethasone + 120 μ g tramazoline + 100 μ gneomycin Symptom scores X-ray changes Microbiology

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Dijkstra 1064 2004 2 DBRCT (n = 162) Following ESS

No difference between

Significant increase in

Significant reduction in

Proportion of patients with improved symptoms

Symptom score

Acoustic rhinometry Endoscopy scores

Middle meatal swabs Blood tests

Nasal airway resistance Mucociliary clearance Sinus x-ray Bacteriology

Active anterior rhinometry Acoustic rhinometry Morning serum cortisol Adverse events

Symptom scores (VAS) Endoscopy score

CT score (Lund-McKay)

Beclamethasone 400 μ g morning, saline placebo evening

dipropionate 200 μ g BID

Fluticasone propionate 400 μ gBID

Parikh 1062 2001 2 DBRCT (n = 22) Fluticasone propionate 200 μ gBID Placebo

Fluticasone propionate 800 μ gBID Placebo

2. 20 μ g dexamethasone, 120 μ g tramazoline 3. Placebo

TABLE IX-26 (Continued)